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the contrary, the ORs were not associated with weight. The adjusted OR
of highest versus lowest weight category was 1.40 (95%CI 0.89,2.21) in
individuals without MetS (Figure), and 0.77 (0.39,1.51) in individuals
with MetS. MetS on the other hand was associated with hand OA,
adjusted for the weight categories; individuals with MetS had a higher
OR for hand OA as compared to individuals without MetS (1.52 (95%CI
1.10,2.09)) (Figure).
Conclusion: This study suggests that in knee OA, whether or not in co-
occurrence with hand OA, mechanical stress is the most important
underlying mechanism, whereas in hand OA alone, systemic processes
might contribute most.
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LONG-TERM EFFECTIVENESS OF GLUCOSAMINE AND CHONDROITIN
IN TREATING KNEE OSTEOARTHRITIS: AN ANALYSIS WITH
MARGINAL STRUCTURAL MODELING
S. Yang y, C.B. Eaton z, T. McAlindon x, K.L. Lapane k. yVirginia
Commonwealth Univ., Richmond, VA, USA; zMem. Hosp. of Rhode Island,
Pawtucket, RI, USA; x Tufts Univ., Medford, MA, USA; kUniv. of
Massachusetts Med. Sch., Worcester, MA, USA
Purpose: In the United States, one third of patients with osteoarthritis
(OA) take glucosamine and chondroitin for arthritis symptoms in the
United States. Despite the prevalent use of these two supplements,
evidence from randomized controlled trials regarding their efﬁcacy is
inconsistent. The purpose of this study was to estimate the long-term
effectiveness of glucosamine and chondroitin in relieving knee symp-
toms and slowing disease progression among patients with knee OA.
Methods: Using data from the Osteoarthritis Initiative, we identiﬁed
1,579 participants who had radiographic knee OA and were not taking
glucosamine or chondroitin at baseline. The 4-year follow-up data were
analyzed. At each annual assessment, use of glucosamine with or
without chondroitin for at least 4 days per week was considered
exposed (GLU/CHON). Knee symptoms were measured with WOMAC
Pain, Stiffness and Physical Function, and structural progression of OA
was measured with joint space width in the medial compartment.
Sociodemographic characteristics (time-invariant) and indices of dis-
ease severity (time-varying) were considered as potential confounders.
To take into account that the indices of disease severity may be
simultaneously confounders and intermediate variables, we used
marginal structural modeling to estimate the long-term treatment
effects. To determine the clinical relevance of our ﬁndings, we com-
pared the estimates with minimal clinically important difference of the
WOMAC subscales (i.e., 1.2, 0.5 and 4.1 for Pain, Stiffness and Function,
respectively).
Results:During the 4-year study period, 280 (18%) participants initiated
treatment, 148 (9%) used the treatment at one assessment, and 65 (4%)
were persistent users at all assessments. After adjustment for potential
confounders with marginal structural models, we found no statistically
or clinically signiﬁcant differences between persistent GLU/CHON users
and never-users in WOMAC Pain: 0.83 (95% CI: 0.01 to 1.68); WOMAC
Stiffness: 0.31 (95% CI: 0.10 to 0.72); WOMAC Function: 1.80 (95% CI:
0.79 to 4.39); or joint space width: 0.04 (95% CI: 0.32 to 0.23).
Conclusions: Long term use of glucosamine with or without chon-
droitin did not appear to relieve symptoms or modifying disease pro-
gression among radiographically conﬁrmed OA patients. Our ﬁndings
are consistent with the results from several long-term clinical trials and
support the latest guidelines for OA treatment which recommend
against using glucosamine and chondroitin. Future qualitative research
is necessary to understand why patients choose to continue using
supplements which lack efﬁcacy.354
EFFECTIVENESS OF INTERNET AND DVD DECISION AIDS FOR
PATIENTS WITH HIP AND KNEE OSTEOARTHRITIS
K.D. Allen y,z, L. Sanders z, M. Olsen y,z, L. Bowlby z, J.N. Katz x,
R.C. Mather, III z, B.J. Powers k, N.R. Sperber y,z, C.I. Voils y,z,
J.W. Williams y,z. yDurham VA Med. Ctr., Durham, NC, USA; zDuke Univ.
Med. Ctr., Durham, NC, USA; xHarvard Med. Sch., Boston, MA, USA; k St.
Luke’s Clinic – Internal Med., Meridian, ID, USA
Purpose: A recent meta-analysis showed that decision aids improve
knowledge, reduce decisional conﬂict, and improve other decision-
making outcomes in the context of chronic health conditions.
However very little is known about the effectiveness of decision aids
for patients with osteoarthritis (OA). This study examined the effects
of internet and DVD format decision aids for patients with hip and
knee OA.
Methods: This study involved n ¼ 155 patients with physician diag-
noses of hip and or knee OA from a general internal medicine clinic and
an orthopedic clinic in the Duke University Healthcare System. Partic-
ipants were randomized to view either the internet or DVD format of a
decision aid for knee / hip OA (according to the most severely affected
joint) from the Informed Medical Decisions Foundation. The Decision
Quality Index – Facts about OA scale DQI Facts; range of 0–100, with
higher scores indicating more knowledge about OA and its treatment)
and Decisional Conﬂict Scale (DCS; range of 0–100, with lower scores
indicating less conﬂict about preferred OA treatment) were adminis-
tered before and immediately after viewing the decision aid, as well as
30 days later. The Preparation for DecisionMaking Scale (PDM; range 0–
100, with higher scores indicating greater helpfulness of the decision
aid) was administered immediately after viewing the decision aid. We
hypothesized that both decision aid formats would be associated with
improvement in outcomes and that changes would be similar between
the two formats. Generalized linear models ﬁt with generalized esti-
mating equations (GEE) were used to examine change in DQI Facts and
DCS over time, both between decision aid groups andwithin the sample
overall. Group differences in the PDM scale were estimated with a
general linear model (GLM).
Results: 60.6% of participants were female, themean agewas 61.8 (SD¼
11.7), 26% had twelve or fewer years of education, and the majority
(82.6%) indicated the knee was their most severely affected joint. Par-
ticipants spent an average of about 30 minutes viewing the internet
versions of the decision aids (range ¼ 17–50 minutes), and the DVDs
were about 45 minutes. There was a signiﬁcant increase in DQI: Facts
scores over time (p < 0.001); scores increased from baseline (mean ¼
50.0, SD ¼ 19.5) to immediate post-decision aid (mean ¼ 66.5, SD ¼
19.6) but declined somewhat by 30-day follow-up (mean ¼ 56.4, SD ¼
19.7). These changes were similar between internet and DVD decision
aid groups (p ¼ 0.46). There was also a signiﬁcant decrease in DCS
scores over time (p < 0.001); scores decreased from baseline (mean ¼
25.0, SD ¼ 26.0) to immediate post-decision aid (mean ¼ 4.7, SD ¼ 11.9)
and remained low at 30-day follow-up (mean ¼ 6.3, SD ¼ 17.0). These
changes were similar between internet and DVD decision aid groups (p
¼ 0.82). PDM scores were relatively high overall but were lower for the
internet format (mean ¼ 74.9, SD ¼ 22.9) than the DVD format (mean ¼
85.2, SD ¼ 13.7, p < 0.001).
Conclusions: Internet and DVD Decision aids are relatively brief and
feasible to deliver in health care settings and are associated with
meaningful improvements in decision-making outcomes for patients
with hip and knee OA. Although there was some attenuation in
knowledge over time, improvements in decisional conﬂict persisted.
The internet and DVD formats yielded similar improvements in
knowledge and decisional conﬂict, but the DVD version was rated as
more helpful in decision making. Further study is needed regarding the
best approaches and formats for incorporating decision aids for hip and
knee OA into clinical care.
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ASSOCIATION OF LARGE JOINT OSTEOARTHRITIS WITH ALL-CAUSE
DEATH: THE JOHNSTON COUNTY OSTEOARTHRITIS PROJECT
R.J. Cleveland, T.A. Schwartz, J.B. Renner, J.M. Jordan, L.F. Callahan.
Thurston Arthritis Res. Ctr., Univ. of North Carolina-Chapel Hill, Chapel
Hill, NC, USA
Purpose: Only a limited number of studies have investigated mortality
among persons with osteoarthritis (OA). Most of these investigations
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S204have been limited by study populations which are not generalizable to
the general population, are limited to small joint OA or did not adjust for
important prognostic factors such as cigarette smoking or body size.
The aim of our study was to examine whether measures of knee and hip
OA at baseline examination are associated with death before ﬁrst fol-
low-up in a large community-based cohort.
Methods: Data from the Johnston County Osteoarthritis Project were
analyzed to investigate the association between large joint OA and
all-cause death. Analyses were carried out using baseline OA data
from 3,465 individuals aged 45 or older who entered the cohort
during the original study enrollment (1990–1997) and new enrolls
recruited during the cohort enrichment (2003–2004). Vital status
was assessed during ﬁrst follow up period (1999–2004 for original
participants; 2007–2010 for new enrolls). Radiographic OA (rOA) was
deﬁned as a Kellgren-Lawrence (KL) grade of 2 in a knee or hip at
baseline clinical assessment. Severe rOA was deﬁned as a KL grade of
3. Symptomatic OA (sxOA) was a subset of those with rOA and
symptoms in the same joint. Multilevel logistic regression models
controlling for the primary sampling unit (PSU) were used to model
the association between rOA measures at baseline and whether a
death occurred before the ﬁrst follow-up evaluation. To explore
whether the association between rOA and mortality differed by sex,
statistical tests for interaction and stratiﬁed logistic models were
used. All models were adjusted for age, sex, obesity, smoking status,
stroke, diabetes and heart disease.
Results: The baseline sample was 63.0% female, 32.4% African-Ameri-
can, with mean age 61.8 years and mean BMI 29.3 kg/m2; 30.7% had
knee rOA, and 25.1% had hip rOA. By the ﬁrst 5-year follow-up, there
were 495 deaths. No associationwas observed between the knee rOA or
hip rOAwith a KL grade of 2 and all-cause death. However, those with
more severe knee rOA (KL grade 3) had a nearly 50% increase in odds
of death and those with severe hip OA were 25% more likely to die
(latter not statistically signiﬁcant, Table 1). Similar results were
observed in analyses evaluating symptomatic severe knee rOA, (OR ¼
1.49, 5% CI ¼ 1.05–2.11). We observed no statistically signiﬁcant effect
modiﬁcation by sex.
Conclusion: Severe knee rOA and sxOAwere positively associated with
death, independently of demographics, smoking, body size, and rele-
vant comorbidities, in a population-based study, suggesting a role for
systemic effects for large joint rOA and symptomatic OA that warrants
further investigation.Table 1
Adjusted odds ratios (aORs) for all-cause death comparing different types of rOA in
the Johnston County Osteoarthritis Project
Deaths/Alive aORy (95% CI) aORx (95% CI)
Has Knee rOA
No 262/1868 Ref. Ref.
Yes 196/815 1.10 (0.88–1.38) 1.14 (0.90–1.45)
Has Severe Knee rOA
No 362/2393 Ref. Ref.
Yes 94/279 1.41 (1.06–1.89) 1.49 (1.10–2.02)
Has Knee SxOA
No 326/2162 Ref. Ref.
Yes 114/475 1.11 (0.86–1.44) 1.11 (0.85–1.46)
Has Severe Knee SxOA
No 372/2433 Ref. Ref.
Yes 68/204 1.45 (1.04–2.01) 1.49 (1.05–2.11)
Has Hip rOA
No 294/1950 Ref. Ref.
Yes 164/733 1.10 (0.87–1.38) 1.10 (0.87–1.39)
Has Severe Hip rOA
No 435/2607 Ref. Ref.
Yes 22/66 1.24 (0.72–2.12) 1.25 (0.72–2.17)
Has Hip SxOA
No 391/2378 Ref. Ref.
Yes 62/261 1.15 (0.83–1.59) 1.06 (0.76–1.47)
Has Severe Hip SxOA
No 443/2608 Ref. Ref.
Yes 10/13 1.25 (0.56–2.82) 1.11 (0.48–2.56)
yAdjusted for age and sex; Controlling for PSU.
xAdjusted for age, sex, BMI, smoking, stroke, diabetes, heart disease; Controlling for
PSU.356
BODY FAT IS AN INDEPENDENT RISK FACTOR FOR OSTEOARTHRITIS
IN THE STATISTICS CANADA CANADIAN HEALTH MEASURES SURVEY
POPULATION
K.H. Collins y, R. Chin y, C. Sanmartin z, R.A. Reimer y, W. Herzog y,
D.A. Marshall y. yUniv. of Calgary, Calgary, AB, Canada; z Statistics Canada,
Ottawa, ON, Canada
Osteoarthritis (OA) is a multifactorial degenerative disease that is the
most common cause of disability in Canada, affecting more than 4.6
million Canadians. By 2040, it is estimated that 1 in 4 Canadianswill have
OA. Recently, the Canadian Joint Replacement Registry, in a study (n ¼
9,706) determined that 54% of individuals who receive knee replace-
ments areobese. Obesity is one of only fewknownmodiﬁable risk factors
forOAand is generallycalculated using bodymass index (BMI is themass
(kg) divided by the height (m) squared; BMI¼ height (kg)/ height2 (m2)).
However, BMI does not account for composition of mass. Increases in
body fat are associated with increased cytokine and adipokine pro-
ductionwhich in turn causes low-grade systemic inﬂammation. By only
evaluating the effect of BMI on OA, valuablemechanistic information for
the role of adiposity in OA may be missed. However, not all OA patients
have increased body fat or metabolic risk factors. Recently, a subtype of
OA,metabolic OA, has been suggested tohave a unique disease trajectory
independent from the mechanical contribution to joint load.
Purpose: The purpose of this study is to determine if body fat, as
measured by anthropometric skinfold, is independently associated with
patient-reported OA status in a cross-sectional study design from sur-
vey data.
Methods: The Canadian Health Measures Survey (CHMS) was the ﬁrst
comprehensive and representative direct health measures study since
the 1978–1979 Canada Health Survey. Approximately 96% of Canadians
were represented and CHMSdatawas collected in two cycles, from2007–
2009 and 2009–2011, at 15 sites. It included household and mobile
examination unit measurements from 11,387 individuals age 3–79 years
old. Data from the two CHMS cycles were combined according to
methods described by Statistics Canada. Inclusion criteria were applied
(age 40–69, valid BMI measurement, valid body fat percentage, not
pregnant, not hemophiliac, no chemotherapy for the last 4 weeks, no
major surgery in the last 3 months, and no neuromuscular disorder,
amputation, vertebral disorder). Individuals with a BMI greater than
30kg/m2 were excluded as they did not have skinfold measurements
taken. Sample estimates were weighted and bootstrapped standard
errors were obtained to account for the survey design. An adjusted
logistic regression model was built using the following factors: age, body
fat percentage (calculated by a 4-point sex-speciﬁc Durnin &Wormersley
equation), waist circumference, absolute weight change (highest adult
weight – lowest adult weight ever), blood creatinine, blood vitamin D,
and hypertension/cardiovascular disease (CVD). These factors were used
to estimate the odds ratio of each factor for the outcome, patient-
reported OA, deﬁned by responding “osteoarthritis” when asked “What
kind of arthritis do you have?”. Type II diabetes was not included in the
model due to low frequency restrictions as outlined by Statistics Canada.
Results: 2656 individuals age 40–69 were included in the analysis.
Approximately 51.5%were female, mean BMIwas 25.3 0.1 kg/m2,mean
body fatwas 27.5 0.2%, 4.5 0.5%hadhypertension/CVD, and3.0 0.5%
had type II Diabetes. The average waist circumference was 87.9  0.4cm
and average absolute weight change was 17.8  0.4 kg. Of these individ-
uals, 236 (8.9%) reported OA. The average body fat percentage of OA
individuals was higher than non-OA (30.2  0.9% compared with 27.3 
0.2%, p ¼ 0.0071), and no differences were found in BMI between the OA
and non-OA groups (24.9 0.3 kg/m2 comparedwith 25.3 0.1 kg/m2, p
¼ 0.25). OA patients had lower blood creatinine (72.3  1 umol/L com-
paredwith 76.0 0.5 umol/L, p¼ 0.003) and increased plasmaVitamin D
(78.1 2.4 nmol/L compared with 67.0 1.1 nmol/L, p¼ 0.0001) non-OA
patients. Individuals with a body fat higher than 31% for females and 21%
for males were found to have a signiﬁcant increase in the likelihood of
patient-reported OA (adjusted OR 2.10, conﬁdence interval 1.04, 4.23)
compared to individualswith lower respective body fat percentage. There
was no relationship between BMI and OA in this population.
Conclusions: Body fat, not BMI, is associated with patient-reported OA
status in a Canadian cohort of BMI  30 kg/m2. Further studies are
necessary to understand the association of OA and body fat, and clas-
siﬁcation of a potential metabolic subtype of OA. However, future
clinical studies should consider body fat, in addition to BMI, to more
adequately capture disease risk.
